Silverfin false false 31/03/2026 01/04/2025 31/03/2026 Mrs I Frisby 25/03/2022 19 June 2026 The principal activity of the company during the financial year was the provision of pharmaceutical consultancy services. NI686898 2026-03-31 NI686898 bus:Director1 2026-03-31 NI686898 core:CurrentFinancialInstruments 2026-03-31 NI686898 core:CurrentFinancialInstruments 2025-03-31 NI686898 2025-03-31 NI686898 core:ShareCapital 2026-03-31 NI686898 core:ShareCapital 2025-03-31 NI686898 core:RetainedEarningsAccumulatedLosses 2026-03-31 NI686898 core:RetainedEarningsAccumulatedLosses 2025-03-31 NI686898 bus:OrdinaryShareClass1 2026-03-31 NI686898 2025-04-01 2026-03-31 NI686898 bus:FilletedAccounts 2025-04-01 2026-03-31 NI686898 bus:SmallEntities 2025-04-01 2026-03-31 NI686898 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 NI686898 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 NI686898 bus:Director1 2025-04-01 2026-03-31 NI686898 2024-04-01 2025-03-31 NI686898 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 NI686898 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 NI686898 1 2025-04-01 2026-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: NI686898 (Northern Ireland)

FQS PHARMA UK LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2026
Pages for filing with the registrar

FQS PHARMA UK LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2026

Contents

FQS PHARMA UK LIMITED

BALANCE SHEET

As at 31 March 2026
FQS PHARMA UK LIMITED

BALANCE SHEET (continued)

As at 31 March 2026
Note 2026 2025
£ £
Current assets
Debtors 3 8,482 15,326
Cash at bank and in hand 14,564 13,009
23,046 28,335
Creditors: amounts falling due within one year 4 ( 3,722) ( 5,378)
Net current assets 19,324 22,957
Total assets less current liabilities 19,324 22,957
Net assets 19,324 22,957
Capital and reserves
Called-up share capital 5 2 2
Profit and loss account 19,322 22,955
Total shareholder's funds 19,324 22,957

For the financial year ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of FQS Pharma UK Limited (registered number: NI686898) were approved and authorised for issue by the Director on 19 June 2026. They were signed on its behalf by:

Mrs I Frisby
Director
FQS PHARMA UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
FQS PHARMA UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

FQS Pharma UK Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Northern Ireland. The address of the Company's registered office and principal place of business is The Mount Business Centre, 2 Woodstock Link, Belfast, BT6 8DD, Northern Ireland, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is stated net of trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets receivable within one year, such as trade debtors and bank balances, are measured at transaction price less any impairment.

Basic financial assets receivable within more than one year are measured at amortised cost less any impairment.

Basic financial liabilities
Basic financial liabilities that have no stated interest rate and are payable within one year, such as trade creditors, are measured at transaction price.

Other basic financial liabilities are measured at amortised cost.

2. Employees

2026 2025
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Debtors

2026 2025
£ £
Trade debtors 4,800 11,890
Prepayments 312 779
Corporation tax 0 2,657
Other debtors 3,370 0
8,482 15,326

4. Creditors: amounts falling due within one year

2026 2025
£ £
Trade creditors 42 49
Amounts owed to director 1,405 1,093
Accruals 2,120 2,200
Other taxation and social security 0 1,849
Other creditors 155 187
3,722 5,378

There are no amounts included above in respect of which any security has been given by the small entity.

5. Called-up share capital

2026 2025
£ £
Allotted, called-up and fully-paid
2 Ordinary shares of £ 1.00 each 2 2

6. Ultimate controlling party

Parent Company:

FQS Industries Limited
Main Street,
Mullinavat
Kilkenny
Ireland

The company, FQS Pharma UK Limited, is owned entirely by its parent company based in Ireland, FQS Industries Limited. This company is jointly owned by Ms Irene and Mr George Frisby.